NCT00874731 2019-05-06
MK-8669-037
Merck Sharp & Dohme LLC
Phase 1 Completed
Clinical Trials
5 trialsNCT01256268 2017-08-30
Carboplatin/Taxol/Ridaforolimus in Endometrial, Ovarian and Solids
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Completed
NCT01071304 2015-04-10
Effect of Ridaforolimus on the Pharmacokinetics of Midazolam (Study MK-8669-044)
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT00093080 2015-02-13
Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT00112372 2015-02-12
Study of Oral Ridaforolimus (AP23573, MK-8669) to Treat Patients With Refractory or Advanced Malignancies (MK-8669-016 AM4)(COMPLETED)
Merck Sharp & Dohme LLC
Phase 1 Completed